At the time of writing, Pacific Biosciences of California Inc [PACB] stock is trading at $3.61, up 4.64%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PACB shares have gain 5.87% over the last week, with a monthly amount drifted -18.51%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pacific Biosciences of California Inc [NASDAQ: PACB] stock has seen the most recent analyst activity on December 14, 2023, when Stephens initiated its Overweight rating and assigned the stock a price target of $11. On December 13, 2023, Wolfe Research initiated with a Peer Perform rating. UBS upgraded its rating to a Buy and decreased its price target to $10 on November 17, 2023. Cantor Fitzgerald upgraded its rating to a Overweight but $11 remained the price target by the analyst firm on October 31, 2023. Bernstein started tracking with a Outperform rating for this stock on September 28, 2023, and assigned it a price target of $11.
For the past year, the stock price of Pacific Biosciences of California Inc fluctuated between $3.21 and $14.55. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Pacific Biosciences of California Inc [NASDAQ: PACB] shares were valued at $3.61 at the most recent close of the market. An investor can expect a potential return of 197.78% based on the average PACB price forecast.
Analyzing the PACB fundamentals
According to Pacific Biosciences of California Inc [NASDAQ:PACB], the company’s sales were 200.52M for trailing twelve months, which represents an 113.35% jump. Gross Profit Margin for this corporation currently stands at 0.27% with Operating Profit Margin at -1.66%, Pretax Profit Margin comes in at -1.59%, and Net Profit Margin reading is -1.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.43 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.45 points at the first support level, and at 3.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.74, and for the 2nd resistance point, it is at 3.86.
Ratios To Look Out For
It is important to note that Pacific Biosciences of California Inc [NASDAQ:PACB] has a current ratio of 7.81. Also, the Quick Ratio is 7.21, while the Cash Ratio stands at 1.9. Considering the valuation of this stock, the price to sales ratio is 4.82, the price to book ratio is 1.38.
Transactions by insiders
Recent insider trading involved Meline David W, Director, that happened on Mar 06 ’24 when 40000.0 shares were purchased., HENRY CHRISTIAN O completed a deal on Mar 04 ’24 to sell 14177.0 shares. Meanwhile, Van Oene Mark sold 9186.0 shares on Mar 04 ’24.
